A major theme of this leukemia SPORE application is translational research that focuses on identifying therapeutically relevant targets for anti-leukemic drug discovery. Each of the projects presented in this application is a testament to a strong collaborative effort between clinicians and basic scientists, which interfaces many aspects of translational research, including oncogenic signaling, epigenetic, experimental therapeutics, and immunology. The Medicinal Chemistry Core integrates the expertise of two laboratories, including medicinal chemistry, molecular and cell biology, and molecular pharmacology (Chen), and computational chemistry and structural biology (Li). In the past few years, this program has developed a series of agents targeting different molecular defects clinically relevant to leukemogenesis, two of which are ready to enter clinical trials in 2009. Thus, this core provides a platform to translate basic science findings from each of these projects into the design and synthesis of small-molecule agents for testing individual hypotheses, and adds an important dimension to expedite the translation from bench to the clinic. Specifically, the following three aims constitute the foci of this Medicinal Chemistry Core with initial emphasis on targeting immunomodulation in tumor-specific T cells and natural killer cells (Project 3), and protein phosphatase (PP) 2A (Pilot Project 2), which will be expanded to address other new molecular targets arising from other projects. Overall, our specific aims include:
Aim 1. To carry out lead optimization of lenalidomidie to develop specific immunomodulatory drugs for chronic lymphocytic leukemia (CLL) therapy (in collaboration with Project 3).
Aim 2. To carry out structural optimization of FTY720 to develop novel PP2A-activating agents (in collaboration with Pilot Project 2).
Aim 3. To provide aspects of medicinal chemistry service including custom synthesis, sample preparations, computational chemistry, and structural biology to interested investigators of this SPORE application (all Projects) and other NCI SPORE and P01 investigators. An example of this is providing OSU-HDAC42 to investigators in Projects 4, 5 and Developmental Project 1. Overall, this unique core will provide members of the SPORE a greater opportunity to translate findings into therapeutic options for patients with leukemia.
This Core provides support in synthetic medicinal chemistry and structural biology/computational chemistry to individual projects to translate basic science findings into the design and synthesis of small-molecule agents for hypothesis testing. Lead compounds with therapeutic potential will further undergo structural optimization to develop potent agents for clinical translation.
|Bhatnagar, Bhavana; Eisfeld, Ann-Kathrin; Nicolet, Deedra et al. (2016) Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol 175:226-236|
|Gao, Keliang; Huang, Xiaomeng; Chiang, Chi-Ling et al. (2016) Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR. Mol Ther 24:956-64|
|Maharry, Sophia E; Walker, Christopher J; Liyanarachchi, Sandya et al. (2016) Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. Cancer Discov 6:1036-51|
|Halley, Patrick D; Lucas, Christopher R; McWilliams, Emily M et al. (2016) Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. Small 12:308-20|
|Mani, R; Yan, R; Mo, X et al. (2016) Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Vet Comp Oncol :|
|Bhatnagar, B; Blachly, J S; Kohlschmidt, J et al. (2016) Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia 30:1586-9|
|Rogers, K A; Ruppert, A S; Bingman, A et al. (2016) Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 30:346-50|
|Goyama, S; Schibler, J; Gasilina, A et al. (2016) UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia 30:728-39|
|Kearney, Cathal J; Lucas, Christopher R; O'Brien, Fergal J et al. (2016) DNA Origami: Folded DNA-Nanodevices That Can Direct and Interpret Cell Behavior. Adv Mater 28:5509-24|
|Tarighat, S S; Santhanam, R; Frankhouser, D et al. (2016) The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia 30:789-99|
Showing the most recent 10 out of 205 publications